Skip to main content
Evidence Snapshot

B2 bradykinin receptor

CHEMBL3157 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3157
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats B2 bradykinin receptor as ChEMBL target CHEMBL3157, mapped to UniProt P30411. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
B2 bradykinin receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3157
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P30411
B2 bradykinin receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why B2 bradykinin receptor matters

As of 2026-09-14

B2 bradykinin receptor is reviewed as B2 bradykinin receptor (UniProt P30411); B2 bradykinin receptor shows approved-linked disease relevance led by angioedema. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 2327 compounds, and 221 assays, with lead potency reaching pChEMBL 10.6.

Disease context
angioedema

B2 bradykinin receptor shows approved-linked disease relevance led by angioedema. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ICATIBANT ACETATE.

Start review with angioedema because it currently carries approved-linked support. Linked drugs include ICATIBANT ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 2327 compounds, and 221 assays for this target. The dominant activity type is KI. CHEMBL2028850 is the current potency anchor at pChEMBL 10.6.

Use CHEMBL2028850 as the tractability anchor when discussing potency (pChEMBL 10.6).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why B2 bradykinin receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30411, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why angioedema is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2327
Total Compounds
221
Total Assays
7
Approved Drugs
IC50: 1191.0, KI: 1199.0, EC50: 2.0, KD: 115.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2028850
 10.6 Ki Approved
No preferred name
CHEMBL1627325
 10.5 EC50 —
No preferred name
CHEMBL1956864
 10.4 Ki —
No preferred name
CHEMBL406291
 10.3 EC50 Clinical
No preferred name
CHEMBL1956855
 10.3 Ki —

Approved Drugs

Structure Compound First Approval
ICATIBANT
CHEMBL2028850
 2008
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3157